Please assess the completion status of the following clinical trial:

Trial Title: P.Vivax Treatment Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with subclinical mono- or mixed P. vivax infections (uPCR) can be enrolled.~* Able to participate as decided by the investigators, and willing to comply with the study requirements and follow-up.~* A participant (or parent/guardian of children below age of consent) is willing and able to give written informed consent to participate in the trial.~Exclusion Criteria:~* Currently pregnant or breastfeeding (female of child-bearing age).~* Inability to tolerate oral treatment.~* Previous episode of haemolysis or severe haemoglobinuria following primaquine.~* Known hypersensitivity or allergy to the study drugs.~* Blood transfusion in last 90 days, since this can mask G6PD deficiency.~* An acute malaria episode requiring treatment.~* A febrile condition due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration).~* Anaemia (Haemoglobin (Hb) \< 9 g/dL~* Presence of any condition which in the judgment of the investigator would place the participant at undue risk or interfere with the results of the study (e.g. serious underlying cardiac, renal or hepatic disease; severe malnutrition; HIV/AIDS; or severe febrile condition other than malaria); co-administration of other medication known to cause haemolysis or that could interfere with the assessment of antimalarial regimens.~* Currently taking medication known to interfere significantly with the pharmacokinetics of primaquine and the schizontocidal study drugs

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention arm (Type: ACTIVE_COMPARATOR): Dihydroartemisinin-piperaquine (DP) therapy plus 14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
- Control arm (Type: PLACEBO_COMPARATOR): Dihydroartemisinin-piperaquine therapy plus 14 days identical placebo not containing primaquine.

Based on this trial design, predict the completion outcome and termination type (if applicable).